Compare Global X FTSE Southeast Asia ETF (ASEA) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X FTSE Southeast Asia ETF vs 22nd Century Group Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | XXII | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $21.53 | $801.00 |
52-Week Low | $16.86 | $3.72 |
Market Cap | — | $1.52M |
Enterprise Value | — | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $21.43, showing minimal daily movement with a 0.14% gain. Technical indicators signal strong bullish momentum with moving averages unanimously positive and ADX readings above 50 indicating a strong trend. The stock faces immediate resistance at $22 with support clustered around $21. A dividend of $0.41 per share is scheduled for July 2026, providing long-term income potential for investors.
The bullish technical setup suggests potential for near-term upside toward resistance levels, though fundamental analysis is limited without current financial metrics. Investors should monitor upcoming earnings reports for revenue growth and profitability trends. Key risks include market volatility and the company's ability to maintain competitive positioning in its sector.
XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.
The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
